Related Experiment Video
Updated: Feb 20, 2026

Author Spotlight: Advancing Real-Time cAMP Detection in Cells Using cADDis Biosensor
Published on: March 22, 2024
Mechanistic basis for the antifibrotic actions of cAMP-based therapies
Marc Peters-Golden1,2, Sean M Fortier3,2
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA petersm@umich.edu.
Abstract:
The human and economic impact of idiopathic pulmonary fibrosis and other interstitial lung diseases is enormous, and available therapies are of limited utility. A decade after the introduction of the first antifibrotic agents, two new agents are on the horizon. Nerandomilast is an inhibitor of phosphodiesterase 4B, while treprostinil is an analogue of prostacyclin. Both agents increase intracellular cAMP. Although the smooth muscle relaxant properties of agents that increase cAMP have long been leveraged for the treatment of airway and vascular diseases, potential antifibrotic actions of cAMP elevation are much less well appreciated by clinicians and researchers. The purpose of this review is to discuss the mechanistic underpinnings for a beneficial role of cAMP in fibrotic lung diseases. We briefly review the pathogenesis of fibrotic lung disease, the anatomy of the cAMP pathway, and the myriad ways in which this pathway is disrupted in fibrotic diseases. We then focus on the pleiotropic actions by which cAMP opposes the aberrant phenotypes of immune cells, fibroblasts, and epithelial cells that characterise fibrotic diseases. Finally, we highlight some unanswered questions about, and future opportunities for optimising, therapeutic interventions that leverage the cAMP pathway.
Insights
New antifibrotic therapies for idiopathic pulmonary fibrosis target the cAMP pathway. Understanding how cAMP elevation combats lung fibrosis offers new treatment strategies.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Cell Biology
Background:
- Idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) have a significant human and economic impact.
- Current therapies for ILDs offer limited utility, highlighting the need for novel treatment approaches.
- Two new antifibrotic agents, nerandomilast and treprostinil, which increase intracellular cyclic adenosine monophosphate (cAMP), are emerging.
Purpose of the Study:
- To elucidate the mechanistic basis for the therapeutic potential of cAMP elevation in fibrotic lung diseases.
- To review the pathogenesis of lung fibrosis, the cAMP signaling pathway, and its dysregulation in disease.
- To explore the multifaceted actions of cAMP in counteracting the cellular abnormalities driving fibrotic lung diseases.
Main Methods:
- Review of existing literature on the pathogenesis of fibrotic lung disease.
- Analysis of the cAMP signaling pathway's structure and function.
- Examination of how cAMP elevation impacts immune cells, fibroblasts, and epithelial cells in fibrotic contexts.
Main Results:
- cAMP signaling is disrupted in fibrotic lung diseases.
- Elevated cAMP levels demonstrate pleiotropic antifibrotic effects by modulating immune, fibroblast, and epithelial cell functions.
- The antifibrotic potential of cAMP elevation is currently underappreciated in clinical and research settings.
Conclusions:
- Targeting the cAMP pathway presents a promising therapeutic strategy for managing fibrotic lung diseases.
- Further research is needed to optimize interventions that leverage cAMP signaling for treating lung fibrosis.
- Understanding the detailed mechanisms of cAMP's antifibrotic actions can guide the development of more effective therapies.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Operant Conditioning Intervention
In operant conditioning, behaviors that are...
Cell-matrix's Response to Mechanical Forces
Anchoring junctions mechanically attach a cell to the...
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...

